Incomplete Spinal Cord Injury

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Connect Biopharma
Connect BiopharmaSAN DIEGO, CA
2 programs
Active tDCSN/A
Anodal tsDCSN/A
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
2 programs
Active tDCSN/A1 trial
Anodal tsDCSN/A1 trial
Active Trials
NCT04977037Completed20Est. Apr 2024
NCT03249454Completed15Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Mission TherapeuticsActive tDCS
Mission TherapeuticsAnodal tsDCS

Clinical Trials (2)

Total enrollment: 35 patients across 2 trials

NCT04977037Mission TherapeuticsActive tDCS

A Telerehabilitation Program for SCI

Start: Jul 2021Est. completion: Apr 202420 patients
N/ACompleted
NCT03249454Mission TherapeuticsAnodal tsDCS

Effects of Transcutaneous Spinal Direct Current Stimulation in Incomplete Spinal Cord Injury

Start: Aug 2017Est. completion: Oct 201815 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space